Cedars Sinai Medical Center

Los Angeles, CA, United States

Cedars Sinai Medical Center

Los Angeles, CA, United States

Time filter

Source Type

Patent
Cedars Sinai Medical Center | Date: 2017-04-19

The invention describes compounds that inhibit both HDAC and GSK3 (i.e., HDAC/GSK3 dual inhibitors). The invention further describes compositions containing these HDAC/GSK3 dual inhibitors, as well as methods and kits using these HDAC/GSK3 dual inhibitors to treat various medical conditions. The invention also provides methods and kits using a HDAC inhibitor and a GSK3 to treat various medical conditions, and compositions containing a HDAC inhibitor and a GSK3. Medical conditions treatable with various embodiments of the invention include but are not limited to caners and tumors.


Patent
Cedars Sinai Medical Center | Date: 2017-04-12

Described herein are methods and compositions using PTH and mesenchymal stem cells (MSCs) for treatment of osteoporosis, bone fractures, and related conditions. Administration of both PTH and MSCs leads to increased homing of MSCs to sites of vertebral bone and rib fracture. The described methods and compositions provide therapeutic approaches that rely, in-part, on stem cell capacity for regeneration and repair. The potential for enhanced bone formation and fracture repair may allow for both preventative and palliative treatments in osteoporotic patients, with combined PTH + MSC therapy producing bone regeneration capacity that is significantly superior to either treatment alone.


Patent
Cedars Sinai Medical Center | Date: 2017-06-14

This invention relates to novel phosphorylation sites in cardiac Troponin I that are associated with the onset of heart failure. The phosphorylation sites, i.e., serine 5, tyrosine 26, threonine 51, serine 166, threonine 181 and/or serine 199, can be used as biomarkers for (i) identifying subjects at risk for the development of heart failure, (ii) treating subjects having a higher than normal level of the biomarker, and (iii) monitoring therapy of a subject at risk for the development of heart failure. Also described are antibodies, reagents, and kits for carrying out a method of the present invention.


This invention provides methods of diagnosing or predicting susceptibility to Inflammatory Bowel Disease by determining the presence or absence of genetic variants in the TL1A gene. In one embodiment, a method of the invention is practiced by determining the presence or absence of TL1A production following Fc-gamma-R activation. In another embodiment, the invention provides methods of treatment of inflammatory bowel disease by inhibition of TL1A.


Patent
Cedars Sinai Medical Center | Date: 2017-03-02

Described herein are methods for treating antibody mediated rejection of transplanted organs using inhibitors of IL-6. In one embodiment, the IL-6 inhibitor is Tocilizumab and is administered simultaneously or sequentially with intravenous immunoglobulin (IVIG).


Patent
Cedars Sinai Medical Center | Date: 2016-08-03

Methods and compositions for treating cancers (e.g., neural cancers) by dendritic cell vaccination are provided herein.


Patent
Cedars Sinai Medical Center | Date: 2017-07-12

The invention provides methods for treating fibrosis, chronic inflammation, chronic pancreatitis, cancer or inflammatory myofibroblastic tumors (IMTs) in a subject in need thereof. The methods include providing a composition comprising a Lyn inhibitor and administering an effective amount of the composition to the subject to treat fibrosis, chronic inflammation, chronic pancreatitis, cancer or inflammatory myofibroblastic tumors (IMTs). fibrosis, chronic inflammation, chronic pancreatitis, cancer or inflammatory myofibroblastic tumors (IMTs).


Patent
Cedars Sinai Medical Center and The Regents Of The University Of California | Date: 2017-07-05

In certain embodiments, this application discloses methods for detecting lung cancer. The method includes characterization of cells extracted from human sputum, which is a valuable tissue surrogate and source of upper respiratory cells that become cancerous early in 5 the process of lung cancer development. The method includes the staining of extracted cells with fluorescent reporters that produce a specific pattern in the nuclei of labeled cells, which can be made visible by light microscopy. The pattern is relevant to a type of epigenetic coding of DNA known as DNA methylation, which changes in specific cells of the lung during cancer development, in comparison to normal respiratory cells.


Patent
Cedars Sinai Medical Center and Stanford University | Date: 2017-07-26

The invention provides methods for treating fibrosis and/or cancer in a subject in need thereof. The methods include providing a composition comprising an inhibitor of IL-4/IL-13 receptor function and administering an effective amount of the composition to the subject to treat fibrosis and/or cancer.


Patent
Emulate Inc. and Cedars Sinai Medical Center | Date: 2017-03-14

The invention relates to culturing motor neuron cells together with skeletal muscle cells in a fluidic device under conditions whereby the interaction of these cells mimic the structure and function of the neuromuscular junction (NMJ) providing a NMJ-on-chip. Good viability, formation of myo-fibers and function of skeletal muscle cells on fluidic chips allow for measurements of muscle cell contractions. Embodiments of motor neurons co-cultures with contractile myo-fibers are contemplated for use with modeling diseases affecting NMJs, e.g. Amyotrophic lateral sclerosis (ALS).

Loading Cedars Sinai Medical Center collaborators
Loading Cedars Sinai Medical Center collaborators